Injecting drug use increases the risk of death in HIV patients on antiretroviral therapy in Vietnam.
| Autor: | Araujo Chaveron, Lucia, Pham, Tram Thi Phuong, Nguyen, Binh Thanh, Tran, Tram Hong, Le, Nhung Thi Hong, Pham, Thang Hong, Ngo, Khanh Phuong, Tong, Ha Thi, Phan, Huong Thi Thu, Ait-Ahmed, Mohand, Nguyen, Tuan Anh, Taieb, Fabien, Madec, Yoann |
|---|---|
| Předmět: |
HIV infection epidemiology
MORTALITY risk factors RISK assessment HEALTH services accessibility INTRAVENOUS drug abuse ANTIRETROVIRAL agents VIRAL load T-test (Statistics) HIV-positive persons SCIENTIFIC observation HUMAN research subjects FISHER exact test HIV infections DISEASE prevalence CHI-squared test DESCRIPTIVE statistics LONGITUDINAL method INFORMED consent (Medical law) VIETNAMESE people DATA analysis software CONFIDENCE intervals PATIENT aftercare PSYCHOSOCIAL factors PROPORTIONAL hazards models REGRESSION analysis DISEASE complications |
| Zdroj: | AIDS Care; May2024, Vol. 36 Issue 5, p631-640, 10p |
| Abstrakt: | The Human Immunodeficiency Virus (HIV) epidemic remains a major public health issue worldwide. In Vietnam, the HIV epidemic is essentially driven by people who inject drugs (PWID). This study aims to compare mortality and loss to follow-up (LTFU) between PWID and other patients. From June 2017 to April 2018, HIV-infected adults were enrolled in a prospective cohort from time of ART initiation in six provinces of North Vietnam. The end date was July 2020. Mortality and LTFU were described using competing-risk survival models. Factors associated with mortality and with LTFU were identified using Cox models with a competing-risk approach. Of the 578 participants, 261 (45.2%) were PWID and almost exclusively male. 49 patients died, corresponding to a mortality rate (95% confidence interval (CI)) of 3.7 (2.8–4.9) per 100 person-months, and 79 were lost to follow-up, corresponding to a rate (95% CI) of 6.0 (4.8–7.4) per 100 person-months. PWID were at higher risk of death but not of LTFU. Overall, LTFU was high in both groups. Latecomers to clinical visits were more at risk of both death and LTFU. Therefore, this should be a warning to clinical teams and preventive actions taken in these patients. Trial registration: ClinicalTrials.gov identifier: NCT03249493.. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|